Pulmonary aspergilloma

Summary

Pulmonary aspergilloma (MONDO:0000266) is a disease. A subtype of aspergillosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary aspergilloma
Mondo ID	MONDO:0000266
EFO	EFO:1001834
MeSH	D055732
DOID	DOID:0050153
UMLS	C2350529
MedGen	390019
GARD	0022738
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	no

Also known as: lung aspergillosis

Disease family

This is a subtype of aspergillosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › aspergillosis › pulmonary aspergilloma

Related subtypes (3): neuroaspergillosis, allergic bronchopulmonary aspergillosis, aspergillus niger infection

Subtypes (2): invasive aspergillosis, malt worker’s lung

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Amphotericin B	Phase 3 (in late-stage trials)
Sodium Chloride	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Opelconazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.